

Dated: January 20, 2026

To,
Corporate Service Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001

Scrip Code: 541299**ISIN:** INE871Z01013**Subject: Outcome of the Board Meeting held on January 20, 2026.**

Dear Sir/Madam,

In continuation of our earlier intimation dated December 16, 2025, and subsequent deferment notice dated December 22, 2025, we wish to inform you that the meeting of the Board of Directors of Dr Lalchandani Labs Limited (“the Company”) was duly held today, i.e., Tuesday, January 20, 2025, to consider and approve matters relating to the proposed Rights Issue of Equity Shares of the Company.

Accordingly, the Board of Directors has, inter-alia, approved the following terms and details in relation to the Rights Issue:

S.No.	Particulars	Details	
A.	Instrument being issued	Fully paid-up Equity Shares of face value ₹10/- each.	
B.	Rights Issue Shares	43,32,000 fully paid-up Equity Shares of face value ₹10/- each, aggregating up to ₹4,33,20,000 (Rupees Four Crore Thirty-Three Lakhs Twenty Thousand only), assuming full subscription.	
C.	Rights Issue Price	₹10/- (Rupees Ten only) per fully paid-up Equity Share. The entire issue price shall be payable at the time of making the application.	
D.	Rights Issue Size	₹4,33,20,000 (Rupees Four Crore Thirty-Three Lakhs Twenty Thousand only), assuming full subscription.	
E.	Rights Entitlement Ratio	1 (One) Rights Equity Shares for every 1 (One) fully paid-up Equity Share held by the eligible shareholders as on the Record Date.	
F.	Record Date	Tuesday, January 27, 2026, for the purpose of determining the shareholders eligible to apply for the Equity Shares in the Rights Issue (“Record Date”).	
G.	Rights Issue Schedule	Issue Opening Date:	Wednesday, February 04, 2026
		Last Date for On-Market Renunciation of Rights Entitlements:	Tuesday, February 17, 2026
		Last Date for Off-Market Renunciation:	Friday, February 20, 2026

		Issue Closing Date	Friday, February 20, 2026
		<i>*The Board of Directors of the Company will have the right to extend the Issue period as it may determine from time to time, provided that this Issue will not remain open in excess of 30 (thirty) days from the Issue Opening Date. Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.</i>	
H.	Outstanding Equity Shares	Prior to the Issue: 43,33,068 fully paid-up Equity Shares of face value ₹10/- each. Post Issue: 86,65,068 fully paid-up Equity Shares of face value ₹10/- each (assuming full subscription and payment of monies).	
I.	ISIN for Rights Entitlement	INE871Z20013	
J.	Other Terms of the Issue	To be included in the Letter of Offer to be filed by the Company.	

Further, in compliance with SEBI Master Circular, SEBI/HO/CFD/PoD-1/P/CIR/2024/0154 dated November 11, 2024, the Company has made necessary arrangements with NSDL and CDSL for the credit of Rights Entitlements (REs) in dematerialized form in the demat accounts of eligible equity shareholders as on the Record Date.

The Rights Entitlements shall be credited prior to the Issue Opening Date under the aforementioned ISIN.

The meeting of the Board commenced at **5:00 P.M.** and concluded at **5:50 P.M.**

The above information is also available on the Company's website: <https://lalchandaniopathlab.com/>

We request you to kindly take the same on record.

Thanking You,
Yours faithfully,

For DR LALCHANDANI LABS LIMITED

ARJAN LALCHANDANI
Managing Director
DIN: 07014579